ACW Appendix 4E and 2022 Annual Report
Filed with ASX · · 76 pages · English
Sydney, 25 August 2022. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce its financial results for the year ended 30 June 2022. The Appendix 4E and 2022 Annual Report documents are attached. ENDS Investors Dr. Steven Gourlay CEO & Managing Director P: +61 2 8964 7401 E. steven.gourlay@actinogen.com.au Michael Roberts Investor Relations M: +61 423 866 231 E. michael.robert
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- ACW CEO presentation to Spark Plus Aust Equities Day
- Application for quotation of securities - ACW
- ACW announces Phase 2 trial designs for AD & MDD
- Actinogen trial results & strategic update presentation
- Actinogen prioritizes Alzheimers Disease & Depression
Later from Actinogen Medical
- Actinogen FY22 Results - Accelerating Clinical Development
- ACW announces positive Alzheimers Disease clinical results
- ACW clinical biomarker study webcast presentation
- R&D tax incentive rebate received
- First patient treated in XanaCIDD Phase 2 Depression Trial
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical